Modelling HIV and MTB Co-Infection Including Combined Treatment Strategies

Santosh Ramkissoon¹, Henry G. Mwambi², Alan P. Matthews¹*

¹ Physics-Durban Academic Group (School of Chemistry and Physics), University of KwaZulu-Natal, Westville Campus, Durban, South Africa, ² School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg Campus, Pietermaritzburg, South Africa

Abstract

A new host-pathogen model is described that simulates HIV-MTB co-infection and treatment, with the objective of testing treatment strategies. The model includes CD4+ and CD8+ T cells, resting and activated macrophages, HIV and Mycobacterium tuberculosis (MTB). For TB presentation at various stages of HIV disease in a co-infected individual, combined treatment strategies were tested with different relative timings of treatment for each infection. The stages were early HIV disease, late HIV disease and AIDS. The main strategies were TB treatment followed by anti-retroviral therapy (ART) after delays of 15 days, 2 months and 6 months. ART followed by TB treatment was an additional strategy that was tested. Treatment was simulated with and without drug interaction. Simulation results were that TB treatment first followed by ART after a stage-dependent delay has the best outcome. During early HIV disease a 6 month delay is acceptable. During late HIV disease, a 2 month delay is best. During AIDS it is better to start ART after 15 days. However, drug interaction works against the benefits of early ART. These results agree with expert reviews and clinical trials.

Introduction

In many developing countries, most notably in Africa where the HIV epidemic is particularly severe, individuals infected with HIV (human immunodeficiency virus) are initiated on ART (anti-retroviral therapy) only when their CD4+ T cell count is below 200 per mm³. At this stage an HIV-infected individual is likely to be co-infected with Mycobacterium tuberculosis (MTB) due to a new MTB infection or latent MTB re-activated due to a weakened immune system. Although current therapies for HIV and TB are effective, there are several problems associated with their combination [1–6].

First, anti-retrovirals have significant side effects which are increased when combined with anti-TB drugs due to overlapping toxicity profiles. Severe side effects may compromise strict adherence to the drug regime resulting in sub-optimal treatment and development of drug-resistant strains of both MTB and HIV, and consequently accelerated progression of both diseases. Second, drug interaction may lead to diminished therapeutic results depending on the choice of drugs. Specifically, some anti-TB drugs reduce concentration of certain anti-retroviral drugs by as much as 90% [4]. Third, after ART the recovery of the immune system may result in Immune Reconstitution Inflammatory Syndrome (IRIS) which is especially problematic for an individual with TB.

Due to these problems the timing of ART relative to TB treatment for co-infection is an important question. As stated in 2010 by Abdool Karim et al. [7], “The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial.” Clinical trials to address this question have been reviewed by Piggott and Karakousis [6] and include the CAMELLIA trial (Cambodian Early versus Late Introduction of Antiretroviral drugs) [8], another recent trial [9], and the CAPRISA (Centre for the AIDS Programme of Research in South Africa) SAPIT trial (Starting Antiretroviral therapy at 3 Points in TB) [5], [7]. SAPIT results [7] support concurrent treatment of HIV and TB for co-infected individuals who have CD4+ T cell counts <500 per mm³. SAPIT had a sequential arm (ART after TB treatment) and two integrated arms (earlier and later ART during TB treatment). The integrated arms proved far superior and the sequential arm had to be stopped. A further analysis [5] of earlier versus later ART in the integrated arms showed that overall there was little difference between outcomes, but individuals with a CD4 count <50 per mm³ benefited from earlier ART (initiated within 4 weeks of the start of TB treatment).

For many years mathematical and computational models have been applied to host-pathogen interaction dynamics and constitute a valuable means of analysis that complements clinical research [10]. Such models have been developed for various aspects of HIV infection [11–27] and for MTB infection [28–38]. Only a few [39–42] have been developed for HIV-MTB co-infection. Of the latter the earliest [40] has four populations: T cells (CD4+ and CD8+ combined), macrophages, HIV and MTB. Bauer et al. [39] have a far more complex MTB component that includes cytokines, similar to the approach in a number of other models [29], [30], [35–38]. The co-infection model of Magomboledze et al. [42] which
builds on their earlier work [18], [32–34], [41] has an intermediate level of complexity with a similar set of populations to Bauer et al. [39] but no cytokines. Regarding modelling of treatment, standard TB treatment only is included in two models [33], [40] and ART only by a number of others [12], [15–18], [23], [25], [26]. Only Magombedze et al. [42] model both ART and TB treatment. They simulated three options: simultaneous treatment, ART only and TB treatment only, and concluded that simultaneous treatment has the best outcome.

We present a new model that builds on previous work [16], [20], [26], [39], [40], [42] and includes elements of other models referenced when described. The biological processes involved in HIV and MTB infection and the response of the immune system to each have been described in various papers [22], [35], [39], [42] and are summarised in the model description in “Methods”.

We include a process to simulate HIV disease progression and model different relative timings of treatment as done in clinical trials. For three timings of TB presentation (early HIV disease, late HIV disease, and AIDS) various treatment strategies are tested. The main strategies start with TB treatment and initiate ART after delays of 15 days, 2 months and 6 months. In addition, to test other possibilities, we include scenarios with ART first followed by TB treatment after 2 months and 6 months.

The overall aim of this paper is to present a new HIV-MTB co-infection model with treatment of both infections, applied to the question of optimal timing of ART relative to TB treatment. These aims have been achieved, firstly by the description and testing of a model that combines HIV and MTB infection, with treatment for both diseases, and secondly by the application of the model to test treatment strategies.

Methods

Model populations and outline

The twelve populations of immune system cells and pathogens in the model are listed with initial values in Table 1 and their interactions are illustrated as a flow diagram in Figure 1. All populations depend on time t and are measured as number per mm³ (or microliter μL). The model is set in the lung compartment where alveolar macrophages and T cells interact with extracellular MTB (population B). HIV (V) is present in the blood which circulates constantly through the body and the lungs. Although HIV density varies with location in the body [13], we consider an average systemic viral load that is correlated with viral load in the peripheral blood. This viral load in turn is correlated with an average HIV infection rate of both CD4+ T cells and macrophages.

There are five varieties of T cells. The first are CD4+ helper T cells (Hd), which are susceptible to HIV infection. When infected by HIV they are reclassified as eclipse-stage cells (He) during the few days that HIV interacts with the cell structures in preparation for budding of new virions from the cell [11], [43]. This includes a biologically-realistic time delay in the infection-replication cycle. Once virion budding begins the eclipse-stage cells become productively infected cells (Hb) that release virions during the one or two days before they die. In addition to death by HIV infection there is also death from viral proteins [44]. There are two small but variable populations of pathogen-specific CD8+ cytotoxic killer T cells (kV for HIV and kB for MTB) that proliferate in response to infected target cells, which they eliminate by lysis.

The macrophage population has five types. Resting macrophages (M0) first encounter MTB in the alveoli. The bacilli are ingested but not destroyed, and they replicate within the macrophages. The macrophages thus become MTB-infected, moving first into an eclipse stage (Mε) during which bacteria are not released, and then into an infected stage (MI) during which bacteria are released by bursting of the macrophage due to a high bacterial load or by natural death of the macrophage. The presence of MTB stimulates recruitment of more macrophages from the blood, and generates an adaptive immune response in which Hb cells activate resting macrophages to become activated macrophages (MA) that successfully phagocytose and destroy bacteria.

Hb cells also stimulate proliferation of MTB-specific killer T cells that lyses M0 cells. On lysis the bacterial load of the infected cell is released and may be phagocytosed. Furthermore, macrophages may be infected by HIV [39–42], [45], [46]. We consider only HIV infection of Mε and MA, which become HIV-infected macrophages (MA). We do not consider HIV-MTB co-infection of macrophages [39] since that adds additional complexity for a small number of cells. However, we do include the effect of MTB infection increasing HIV production [39], [47] as one of the mutually aggravating features of co-infection.

Modelling immune system collapse

It is difficult to model progression of HIV infection to AIDS because the mechanisms are not fully understood. Motivated by...
Modelling treatment

TB treatment is simulated by considering bacteriostatic and bactericidal drug action. Bacteriostatic drugs inhibit growth of MTB and are modelled by limiting bacterial growth by the parameter $\epsilon_B$ which ranges from 0 to 1 with 1 corresponding to 100% effective. Bactericidal drugs kill MTB and are modelled by the parameter $\epsilon_C$ in a bacterial death term.

Anti-retroviral therapy (ART) is simulated by considering both protease and reverse transcriptase inhibitors, and using effectiveness parameters [26], [42]. Protease inhibitors render HIV virions non-infectious, an action modelled with the parameter $\epsilon_P$. Reverse transcriptase inhibitors block HIV infection of T cells and macrophages, modelled with the parameter $\epsilon_R$. Both parameters range from 0 to 1, with 1 corresponding to 100% effective.

Interaction between anti-retrovirals (ARVs) and anti-TB drugs may reduce ARV efficacies [1–4]. For example reduction of ARV absorption due to the commonly-used anti-TB drug rifampin varies from 30–90% for several protease inhibitors and from 20–96% for some reverse transcriptase inhibitors [4]. We do not attempt to model the various drug combinations, but as a simplification, in order to simulate a reasonable worst-case scenario, we use a single efficacy reduction parameter $d$ that reduces both $\epsilon_P$ and $\epsilon_R$. If $d = 0$ there is no drug interaction and full drug efficacy. ART is thus represented by a combined factor that reduces HIV infection, modified by drug interaction, given by

$$\beta_V = [1 - (1 - d)\epsilon_R][1 - (1 - d)\epsilon_P].$$

Model equations

First we define functions that will simplify the population rate of change equations. Initial immune system response at the start of infection is simulated by multiplying several response terms by a phasing-in function $\rho_{B,V}$ (range 0–1, median $T_{IR}$) that becomes non-zero after the infection date $t_{INF}$ where $INF = MTB$ or HIV:

$$\rho_{B,V} = 1 - \exp\left(-\frac{\left(\frac{t - t_{INF}}{T_{IR}}\right)^2}{2}\right) \text{if } t > t_{INF}, \text{ or 0 otherwise}. \quad (5)$$

The general health of the immune system is represented by

$$h = \frac{H_S}{H_{df}} \quad (6)$$

where $H_{df}$ is the disease-free CD4$^+$ T cell density (set at 1000 mm$^{-3}$). We assume that several immune system responses are proportional to $h$. We model reduction of viral infection and replication rates due to non-cytotoxic action of $K_V$ [11], [42] by defining factors

$$f_I = \frac{1}{1 + \rho_V \rho_I K_V} \quad \text{and} \quad f_R = \frac{1}{1 + \rho_V \rho_R K_V}. \quad (7)$$

Furthermore, HIV production is increased due to MTB infection [39], [47] by the factor

$$R_B = 1 + \rho_B \frac{B}{B_{max}} \quad (8)$$

where $B_{max}$ is a scale constant also used for setting a logistic limit to bacterial load.

---

Table 1. Population variables and initial values.

| Symbol | Description | Initial value (mm$^{-3}$) |
|--------|-------------|--------------------------|
| $H_S$ | Susceptible CD4$^+$ T cells | 1000 |
| $H_I$ | HIV-infected T cells in eclipse stage | 0 |
| $H_P$ | HIV-infected T cells in productive stage | 0 |
| $K_V$ | HIV-specific CD8$^+$ cytotoxic T cells | 10 |
| $K_B$ | MTB-specific CD8$^+$ cytotoxic T cells | 10 |
| $M_R$ | Resting macrophages | 200 |
| $M_T$ | MTB-infected macrophages in eclipse stage | 0 |
| $M_P$ | MTB-infected macrophages in productive stage | 0 |
| $M_A$ | Activated macrophages | 0 |
| $V$ | HIV virions | 0.1 |
| $B$ | MTB bacteria | 10 |

where $t_{HIV}$ is the HIV infection date and time is in years. We then specify the replication increase factor $R_V$ in terms of a coefficient $p_V$ and a Weibull cumulative distribution function $Q(V_T)$ with scale parameter $\sigma$ and shape parameter $k$:

$$R_V = 1 + p_V Q \text{ where } Q(V_T) = 1 - \exp\left(-\left(\frac{V_T}{\sigma}\right)^k\right). \quad (2)$$

Weibull functions are often used to model systems with failure times, and have been used for example to simulate progression to AIDS in epidemiological models at population level [48], [49].

HIV infection is understood to eventually exhaust the capacity of the body to produce CD4$^+$ T cells [50], [51] and following but modifying the idea of Kirschner [40] this is modelled by a capacity reduction factor $R_C$:

$$R_C = \frac{1}{1 + Q}. \quad (3)$$

This diminishes the source $s_M$ of CD4$^+$ T cells by up to 50% as HIV infection progresses. Since in this model not all capacity is lost, an individual may experience a degree of immune reconstitution after ART that depends on degree of disease progression at the time of treatment.
Now we describe the population rate of change equations. The CD4+ helper T cell population is governed by

$$\frac{dH_S}{dt} = R_{C5H} - \mu_{H5} H_S + r_H H_S \left(1 - \frac{H_S}{H_{max}}\right)$$

$$+ \left(\frac{\rho_B V + \rho_B B}{V + B + C_H}\right) - \beta_{f1} \frac{\lambda_{MH} V H_S}{V - \lambda_V H_S}.$$ 

(9)

The first term is the source, modified by the capacity reduction factor $R_{C5}$, and the second term is natural death. The third term is a proliferation response, where proliferation is proportional to a Michaelis-Menten function of both pathogens [40], and a logistic growth limit $H_{max} = 1500$ is included [20] since the population does not grow without bound. The immune response factors $\rho_V$ and $\rho_B$ are attached separately to each pathogen. The fourth term is infection by HIV, reduced both by ART and CD8+ T cell non-cytotoxic action. The final term is killing of CD4+ T cells by toxic HIV virions [44], assumed to be proportional to viral load. The eclipse-stage CD4+ T cells are governed by an equation with a gain term for infection and a loss term for transition to the productively infected stage:

$$\frac{dH_E}{dt} = \beta_{f1} \frac{\lambda_{MH} V H_S}{V - \lambda_V H_S} - \mu_{HE} H_E.$$  

(10)

The equation for productively infected T cells is

$$\frac{dH_V}{dt} = \mu_{HE} H_E - \mu_{HV} V - \frac{z_K}{z_K + \lambda_V} K_V H_V$$

(11)

where the first term is gain from the eclipse stage, the second is death due to budding of virions, and the last is loss due to lysis by $K_V$. The lysis term could in principle have a Michaelis-Menten factor with half-saturation constant $C_L$ but the simpler form is suitable since $H_V \ll C_L$ (see “Parameters”). The term with the Michaelis-Menten factor is $K_V N_L H_V/(H_V + M + C_L)$ which is approximately $K_V N_L H_V/C_L$, where $N_L$ is the maximum number of infected cells lysed per day by one CD8+ T cell. Then the lysis rate is given by

$$z_K = \frac{N_L}{C_L}.$$ 

(12)

The CD8+ T cells, HIV-specific and MTB-specific respectively, are governed by the following equations:

$$\frac{dK_V}{dt} = s_K - \mu_K K_V + \rho_V r_K K_V \left(1 - \frac{K_V}{K_{max}}\right) \frac{H_V + M}{H_V + M + C_K}$$

(13)

and

$$\frac{dK_B}{dt} = s_K - \mu_K K_B + \rho_B r_K K_B \left(1 - \frac{K_B}{K_{max}}\right) \frac{M}{M + C_K}.$$ 

(14)

Each equation has a source term, a natural death term, and a proliferation term similar to that of Magombedze et al. [42] but with a Michaelis-Menten function of infected cells. As for $H_S$, a logistic limit factor is included with a population upper limit $K_{max}$, because the populations do not grow without bound.

For resting macrophages, the recruitment term is given first as

$$R_{MR} = s_M \left(1 + \frac{r_M}{B + C_M}\right).$$ 

(15)

The macrophage level is increased by attraction of macrophages to the infection site [47]. In several recent models [29], [35], [36], [38] recruitment depends on the level of MTB via the levels of activated and infected macrophages. Here, the disease-free source $s_M$ is amplified by a Michaelis-Menten function of bacteria ($B$). The resting macrophage evolution equation is then

$$\frac{dM_R}{dt} = R_{MR} - h_\rho B M_R B + C_A - \mu_M M_R - \beta_{f1} \frac{\lambda_{VM} V M_R}{V + M + C}.$$ 

(16)

Term 1 is recruitment. Term 2 is loss due to activation proportional to an activation coefficient $s_M$, triggered by $B$ and helped by CD4+ T cells. Term 3 is natural death. Term 4 is HIV infection with a macrophage-specific infection rate $\lambda_{VM}$ and the same ART and CD8+ reduction factors as for T cell infection. Term 5 is MTB infection, with rate $\lambda_B$ related to three other model parameters by

$$\lambda_B = \frac{N_B}{N_B C_A}.$$ 

(17)

The rationale is that each macrophage ingests an average $N_B B/(B + C_A)$ bacilli day$^{-1}$, up to a maximum of $N_B$. In the scenarios that will be simulated, $B$ is well below the half-saturation level $C_A$ so the approximation $N_B B/C_A$ is acceptable (see “Parameters”). Then on average one macrophage is infected for every $N_B$ bacilli ingested.

Macrophages in the eclipse stage of MTB infection have an equation similar to Eq. (11) but with $B$ as the pathogen:

$$\frac{dM_E}{dt} = \lambda_B B M_R - \mu_ME M_E.$$ 

(18)

The equation for MTB-infected macrophages has a form similar to Eq. (11):

$$\frac{dM_B}{dt} = \mu_ME M_E - \mu_MB B - \frac{z_K}{z_K + \lambda_V} K_V M_B.$$ 

(19)

Activated macrophages have the following equation, with the activation gain term from Eq. (16), a natural death loss term, and an HIV infection loss term:

$$\frac{dM_A}{dt} = h_\rho B M_R B + C_A - \mu_M A - \beta_{f1} \frac{\lambda_{VM} V M_A}{V + M + C}.$$ 

(20)

HIV-infected macrophages have an equation of similar form to Eq. (11), with gain from HIV infection of both resting and active macrophages:

$$\frac{dM_V}{dt} = \beta_{f1} \frac{\lambda_{VM} V (M_R + M_A) - \mu_M V - \frac{z_K}{z_K + \lambda_V} K_V M_V}{V + M + C}.$$ 

(21)

HIV virions have an equation with a gain term due to viral production from HIV-infected T cells and macrophages (where $N_{H,M}$ are burst size per infected cell), and a loss term due to the...
combined effects of natural decay and clearance by neutralising antibodies:

\[
\frac{dV}{dt} = R_f B R_f s_k (N_H \mu_H H_V + N_M \mu_M M_V) - \mu_V V. \tag{22}
\]

The production term is increased by the disease progression factor \(R_f\) and the MTB increase factor \(R_b\). It is decreased by the CD8+ T cell non-cytotoxic factor \(f_c\). The MTB population has a growth term due to intracellular replication given by

\[
B_{IR} = N_b H_M B_M + N_K I_k K_B M_B. \tag{23}
\]

The first term is release of \(N_b\) bacilli per burst macrophage and the second term is release of \(N_K\) bacilli per macrophage after lysis by a CD8+ T cell, where \(N_b < N_p\). The MTB evolution equation is

\[
\frac{dB}{dt} = (1 - e_b) B_{IR} - \lambda_b B (M_B + M_A) - \mu_p B^2 \frac{B}{B_{\text{max}}} - e_c B. \tag{24}
\]

Term 1 represents intracellular growth that is reduced with the bacteriostatic parameter \(e_b\). Term 2 is loss due to phagocytosis by \(M_B\) and \(M_A\). As described for Eq. (16), each macrophage ingests approximately \(N_b B/C_b\) bacilli day\(^{-1}\) so the phagocytosis rate \(\lambda_b\) is related to other parameters by

\[
\lambda_b = \frac{N_b}{C_b} = N_i \lambda B. \tag{25}
\]

Term 3 in Eq. (24) sets a logistic limit to bacterial level in infected but not yet necrotic tissue, and represents loss of bacteria by dissemination, flushing, or loss to necrotic regions. It has the same form as in Kirschner [40] and is useful in the model to prevent unbounded growth; high but limited growth will be sufficient to represent active infection that needs treatment. It has quadratic form so that it acts preferentially at high levels of \(B\) and exerts less influence at lower levels during development of infection. The final term is bactericidal drug action.

An analysis of the model is given in Appendix S1.

Parameters

The model’s parameters and their values are listed in Table 2, and are explained below.

For CD4+ T cells the initial and disease-free equilibrium cell count \(H_g = 1000\) mm\(^{-3}\) [23]. The proliferation parameter \(t_H = 0.01\) day\(^{-1}\) [16], similar to the 0.02 value of Kirschner [40], and the corresponding half-saturation constant \(C_{H^2} = 1000\) pathogen mm\(^{-3}\) [40]. This represents proliferation of the 1–2% of antigen-specific cells within the total CD4+ population. The upper limit \(H_{\text{max}} = 1500\) mm\(^{-3}\) [20]. Natural death rate \(\mu_{H^2}\) is 0.01 day\(^{-1}\) [14], [23]. Consequently the source \(s_H = \mu_{H^2} H_g = 10\) cells mm\(^{-3}\) day\(^{-1}\).

The eclipse stage of a CD4+ T cell after infection by HIV lasts about 1 day [11]. In the model the loss rates act as soon as a cell enters a new compartment so to counter this effect we set the total eclipse time to about 3 days, with the transition rate to being productively infected \(\mu_{H^2}\) is 0.25 day\(^{-1}\). Hence the sum of halves of eclipse and productively infected cells (discussed next) is about 4 days, consistent with the 3–4 days reported for a complete cycle from infection to budding [43]. The HIV-infected CD4+ T cell death rate due to budding of virions is \(\mu_{H^2} = 0.5\) day\(^{-1}\) (median life-span 1.4 days), consistent with values used in a number of models [11], [13], [19], [22], [23].

CD8+ T cells number about 500 mm\(^{-3}\) [52] of which about 2.5–3% are antigen-specific. We set the disease-free resting level \(K_g = 10\) cells mm\(^{-3}\), just lower than the 12.5–15 value corresponding to 2.5–3% but somewhat higher than 5 set by Magombedze et al. [42]. These cells proliferate in response to antigen at a rate \(t_k = 1.5\) day\(^{-1}\) [11]. They do not increase without bound so following the method of Perelson et al. [20] we set an upper limit at \(K_{\text{max}} = 100\) cells mm\(^{-3}\) which is the estimated upper level of 20% of CD8+ T cells specific to an antigen. The half-saturation constant (infected cell level) to trigger response is estimated as \(C_k = 2.5\) cells mm\(^{-3}\). Althaus and De Boer [11] have a similar Michaelis-Menten constant which depends on cytotoxic efficacy and we have therefore set our value to have efficacy that corresponds to observed low levels of infected cells. Natural death rate is \(\mu_k = 0.5\) day\(^{-1}\), within the 0.3–1 range used by other models [11], [22] and consequently the source \(t_k = \mu_k K = 5\) cells mm\(^{-3}\) day\(^{-1}\).

The maximum number of cells lysed by a CD8+ cytotoxic T cell is estimated as a maximum of \(N_l = 50\) infected cells per cytotoxic cell per day [11]. This is much higher than values in the range 0.5–3 used in other models [30], [39] and reported by experiment [52] but it is a maximum rate not attained in our simulations so its high value does not play a significant role. Althaus and De Boer [11] present a wide range for the half-saturation constant (1–10\(^9\) cells mm\(^{-3}\) depending on cytotoxic efficacy. We set this as \(C_l = 2500\) infected cells mm\(^{-3}\), consistent with 50 cells lysed by the maximum of 100 cytotoxic cells mm\(^{-3}\) in the model. In principle, number of cells lysed per day per mm\(^3\) could be modelled with a Michaelis-Menten saturation function \(N_l I_K/(I + C_l)\) where \(I\) is the infected cell density. However, in the simulations \(I < C_l\) so the approximation \(N_l I_K/C_l \approx t_k I K\) is suitable, where the lysis rate \(t_k = N_l/C_l = 0.02\) CD8– day\(^{-1}\).

Viron burst size from an infected T cell is \(N_{HI} = 1000\) [16], [42], within the 100–1000 range presented by Kirschner [40] for both T cells and macrophages. This is not a narrowly-determined parameter; values used in recent models range from 100 [22] to 50 000 [19]. The burst size from an HIV-infected macrophage is \(N_{HI} = 800\) [42]. The budding period lasts from about a day for T cells to months for macrophages.

Viron clearance rate due to natural viroin decay and neutralising antibodies is \(v_t = 4\) day\(^{-1}\) [22] which is close to values used in other work [14], [39]. This parameter varies in different models, from as low as 1.5 [42] to as high as 23 [11], [23]. We chose the intermediate value which together with other parameter values produces a reasonable pattern of HIV infection. HIV infection rate of T cells is \(z_{HI} = 10^{-4}\) virion–1 day\(^{-1}\), close to 9\times10\(^{-5}\) used by Bauer et al. [39] and in the range they present of 10\(^{-5}\)–10\(^{-4}\). Rate of HIV infection of macrophages is \(z_{HI} = 10^{-5}\) virion–1 day\(^{-1}\), set at 10% of the T cell rate [42].

Death rate of CD4+ T cells due to toxic HIV proteins (uninfected bystander death [44], which Alimonti et al. [44] argue is at least as large as death by infection) is estimated as \(v_{HI} = 10^{-4}\) virion–1 day\(^{-1}\), equal to the HIV infection rate. Our model also includes non-cytotoxic action of CD8+ T cells that reduces viral infection and replication [11], [39], [42]. We set \(p_l = p_g = 0.1\) (cell/\(\text{mm}^3\))\(^{-1}\), similar to those of Magombedze et al. [42] who estimate \(p_l = 0.075\) and \(p_g = 0.05\) for T cells and \(p_l = 0.85\) and \(p_g = 0.075\) for macrophages.

The initial and disease-free level of resting macrophages was set at \(M_g = 200\) cells mm\(^{-3}\) [14]. In other models this ranges from 100 [40] to 300 [39], and as high as 500 [35]. Since macrophages are recruited to an infection site in response to pathogen we allow for an increase of the source function by a factor 10, so \(t_M = 9\). The half-saturation recruitment constant was estimated at \(C_M = 500\)
### Table 2. Parameters used in the simulations.

| Symbol | Description | Value |
|--------|-------------|-------|
| $s_H$ | Source rate of CD4+ T cells | 10 cells mm^{-3} day^{-1} |
| $s_K$ | Source rate of CD8+ T cells | 5 cells mm^{-3} day^{-1} |
| $s_M$ | Source rate of resting macrophages | 2 cells mm^{-3} day^{-1} |
| $r_H$ | Proliferation response rate of CD4+ T cells | 0.01 day^{-1} |
| $r_K$ | Proliferation response rate of CD8+ T cells | 1.5 day^{-1} |
| $r_M$ | Macrophage recruitment factor | 9 |
| $a_M$ | Activation rate of macrophages | 0.1 day^{-1} |
| $C_A$ | Half-saturation constant for macrophage activation | 500 bacilli mm^{-3} |
| $C_H$ | Half-saturation constant for CD4+ T cell proliferation | 10000 pathogen mm^{-3} |
| $C_K$ | Half-saturation constant for CD8+ T cell response | 2.5 cells mm^{-3} |
| $C_M$ | Half-saturation constant for macrophage recruitment | 500 bacilli mm^{-3} |
| $C_L$ | Half-saturation constant for lysis | 2500 cells mm^{-3} |
| $C_D$ | Half-saturation constant for phagocytosis | 5000 bacilli mm^{-3} |
| $H_{HS}$ | Death rate of uninfected CD4+ T cells | 0.01 day^{-1} |
| $H_{HE}$ | Transition rate of eclipse T cells | 0.25 day^{-1} |
| $H_{HV}$ | Death rate of HIV-infected T cells | 0.5 day^{-1} |
| $H_{KB}$ | Death rate of CD8+ T cells | 0.5 day^{-1} |
| $H_{MB}$ | Death rate of resting macrophages | 0.01 day^{-1} |
| $H_{ME}$ | Transition rate of eclipse macrophages | 0.05 day^{-1} |
| $H_{MA}$ | Burst rate of MTB-infected macrophages | 0.1 day^{-1} |
| $H_{MA}$ | Death rate of activated macrophages | 0.1 day^{-1} |
| $H_{MV}$ | Death rate of HIV-infected macrophages | 0.01 day^{-1} |
| $l_{HV}$ | Decay and clearance rate of HIV virions | 4 day^{-1} |
| $l_B$ | Loss rate of MTB | 0.1 day^{-1} |
| $l_{H_{HS}}$ | HIV infection rate of CD4+ T cells | 10^{-4} virion^{-1} day^{-1} |
| $l_{H_{HV}}$ | HIV infection rate of macrophages | 10^{-4} virion^{-1} day^{-1} |
| $l_B$ | MTB infection rate of $M_b$ | 8×10^{-3} bacillus^{-1} day^{-1} |
| $N_{HV}$ | HIV burst from HIV-infected T cell | 1000 virions cell^{-1} |
| $N_{MV}$ | HIV burst from HIV-infected macrophage | 800 virions cell^{-1} |
| $N_B$ | Maximum number of bacilli phagocytosed per $M_b$ | 10 bacilli M^{-1} day^{-1} |
| $N_I$ | Number of ingested bacilli per MTB infection | 25 bacilli |
| $N_R$ | Number of bacilli released by lysis of $M_R$ by $K_B$ | 35 bacilli cell^{-1} |
| $N_B$ | Number of bacilli released by burst of $M_B$ | 50 bacilli cell^{-1} |
| $N_C$ | Maximum cells lysed by one CD8+ T cell $K_{RV}$ | 50 cells CD8^{-1} day^{-1} |
| $P_B$ | Phagocytosis rate of $B$ by $M_{b}$ | 0.002 M_{b}^{-1} day^{-1} |
| $P_B$ | CD8+ T cell lysis rate | 0.02 CD8^{-1} day^{-1} |
| $P_B$ | Death rate of CD4+ T cells $H_S$ due to viral proteins | 10^{-4} virion^{-1} day^{-1} |
| $p_1$ | HIV infection reduction coefficient | 0.1 (cell/mm^3)^{-1} |
| $p_1$ | HIV replication reduction coefficient | 0.1 (cell/mm^3)^{-1} |
| $p_B$ | HIV replication increase parameter | 5 |
| $p_B$ | MTB-induced HIV replication increase factor | 0.2 |
| $H_{max}$ | Disease-free CD4+ T cell level | 1000 cells mm^{-3} |
| $K_{max}$ | Maximum CD4+ T cell level | 1500 cells mm^{-3} |
| $R_{max}$ | Disease-free CD8+ T cell level | 10 cells mm^{-3} |
| $K_{max}$ | Maximum CD8+ T cell level | 100 cells mm^{-3} |
| $M_{max}$ | Disease-free macrophage level | 200 cells mm^{-3} |
| $B_{max}$ | Scale constant of MTB | 1000 bacilli mm^{-3} |
| $B_{cure}$ | MTB threshold for TB cure | 1 bacillus mm^{-3} |
| $V_{ref}$ | Viral load reference level | 100 virions mm^{-3} |
bacilli mm\(^{-3}\) which is approximately half the maximum level attained in the simulations (higher levels would be associated with large necrotic tubercles and cavities). Natural death rate \( \mu_{MR} = 0.01 \text{ day}^{-1} \) [35], [42] so \( s_M = \mu_{MR} u_d = 2 \text{ cells mm}^{-3} \text{ day}^{-1} \).

The activation rate of resting macrophages \( a_M = 0.1 \text{ day}^{-1} \) [39]. The death rate \( \mu_{MA} = 0.1 \text{ day}^{-1} \), close to 0.07 used by Bauer at al. [39]. Half-saturation constant for activation \( C_d = 500 \text{ bacilli mm}^{-3} \) [Bauer at al. [39] give a wide range of \(10^4\)]. Macrophages in the eclipse stage last about a week before dying [28] so the transition rate of \( M_d \) to productively MTB-infected is \( \mu_{ME} = 0.05 \text{ day}^{-1} \). Death rate of MTB-infected macrophages \( (M_B) \) due to bursting is \( \mu_{MB} = 0.1 \text{ day}^{-1} \) [35], within the range 0.001–0.1 [39]. The death rate of HIV-infected macrophages due to virion budding is \( \mu_{MB} = 0.01 \text{ day}^{-1} \) [35], [42], within the range 0.001–0.1 [39].

MTB burst size \( N_B = 50 \) [35], [42] is the number of bacilli released when an MTB-infected macrophage bursts due to a large bacillary load. A macrophage has a carrying capacity of 10–50 bacilli [39] and we assume an average maximum phagocytosis of \( N_B = 10 \text{ bacilli macrophage}^{-1} \text{ day}^{-1} \). Following Marino and Kirschner [35] and Magombedze et al. [42] we set the number of bacilli ingested at infection at \( N_i = N_B/2 = 25 \), and then the number of bacilli released on lysis of an MTB-infected macrophage is \( N_B = 35 \), intermediate between \( N_i \) and \( N_B \). This is consistent with the scheme [28] whereby a macrophage becomes necrotic with a load of 32 bacilli. The half-saturation phagocytosis constant is estimated as \( C_a = 5000 \text{ bacilli mm}^{-3} \). These values are as above but reasonable indicators of the complex underlying process. The phagocytosis rate \( f_d \) is calculated from Eq. (25) as \( f_d = N_d/C_a = 0.002 \text{ macrophage}^{-1} \text{ day}^{-1} \). As discussed for lysis, this is an approximation of a Michaelis-Menten function \( N_a MB/(B + C_a) \) where \( B \ll C_a \). In the simulations, \( B \) does not exceed 1500 mm\(^{-3}\) so it is well below \( C_a \) although it starts to be comparable to \( C_a \). Making the approximation produces little difference in simulation results and also simplifies analysis of the model. MTB infection rate is calculated from Eq. (17) as \( \lambda_B = N_b/(N(C_B) = 8 \times 10^{-3} \text{ bacillus}^{-1} \text{ day}^{-1} \). MTB loss rate we estimate as \( \mu_B = 0.1 \text{ day}^{-1} \).

We conclude with miscellaneous parameters. Those for treatment efficacy were set to \( e_p = e_R = 0.75, e_N = 0.5 \), and \( e_s = 0.5 \text{ day}^{-1} \) (compare with e.g. overall \( e_{AB} = 0.85 \) [23]) which cleared both infections. The drug interaction parameter \( d = 0 \) for no interaction and we set \( d = 0.75 \) for drug interaction. For modelling progression to AIDS, \( V_{inf} = 100 \text{ virions mm}^{-3} \) to obtain with the other parameters a disease lifetime of about 10 years, and the Weibull cumulative distribution function has scale parameter \( \sigma = 11.362 \text{ years and shape parameter } k = 2.871 \) which result in a median of 10 years and a 10%–90% width of 10 years. The viral production increase parameter is set to \( \nu_{PR} = 5 \) in order to produce a 6-fold increase (maximum \( R_1 = 6 \)). These values were selected to produce a pattern consistent with observation. The parameter that determines increase in virion production due to MTB infection was estimated as \( \mu_B = 0.2 \) to produce a significant but not dominant effect, and the scale parameter \( B_{min} = 1000 \text{ bacilli mm}^{-3} \). Median immune response time \( T_R = 14 \text{ days} \). The MTB cure parameter was set arbitrarily to \( B_{min} = 1 \text{ bacillus mm}^{-3} \) and undetectable viral load threshold \( V_{inf} = 0.05 \text{ mm}^{-3} \) (50 per millilitre).

### Results

All simulations were run by solving Eqs. (9–11, 13, 14, 16, 18–22, 24) numerically with a C++ program. The algorithm is a first-order Euler integrator with time step \( \Delta t = 1 \text{ minute} \). If a population variable \( U_n \) is known at time \( t_n \), then after one time-step

\[
U_{n+1} = U_n + \Delta t \left( \frac{dU}{dt} \right)_n.
\]

Although this is a low-order method the small time-step keeps the error to a total of 0.24% for an exponential growth rate of 1 day\(^{-1}\) that produces a 1000-fold increase over 7 days. This rate is larger than any in the simulations and is approached only by \( V \) during primary infection.

### Simulation of HIV and MTB infection without treatment

Simulation of HIV infection only is shown in Figure 2A. Time \( t \) is measured in years, with HIV infection started at \( t = 0 \) by setting viral load \( V = 0.1 \text{ mm}^{-3} \). The model approximates HIV infection dynamics in a manner consistent with clinical observations. Initially (during primary infection, expanded in the inset) there is a short-lived spike in \( V \) which settles down to a quasi steady-state value (the “set-point”) in the early phase of the asymptomatic

---

**Table 2. Cont.**

| Symbol | Description | Value |
|---|---|---|
| \( V_{inf} \) | Undetectable viral load threshold | 0.05 virions mm\(^{-3}\) |
| \( T_R \) | Time for half-saturation of immune response | 14 days |
| \( T_{median} \) | Median of Weibull function for \( V \) increase | 10 years |
| \( T_{width} \) | Width (10%–90%) of Weibull function | 10 years |
| \( \sigma \) | Scale parameter of Weibull function | 11.362 years |
| \( k \) | Shape parameter of Weibull function | 2.871 |
| \( \nu_P \) | Protease inhibition drug efficacy | 0 or 0.75\(^b\) |
| \( \nu_E \) | Reverse transcriptase inhibition drug efficacy | 0 or 0.75\(^a\) |
| \( \nu_S \) | Bacteriostatic TB drug rate | 0 or 0.5 \(^b\) |
| \( \nu_S \) | Bacteriostatic TB drug efficacy | 0 or 0.5 \(^b\) |
| \( d \) | Drug interaction parameter | 0 or 0.75\(^b\) |

\(^a\) \( M_i \) denotes “macrophage”.
\(^b\) 0 for inactive, >0 for active.

doi:10.1371/journal.pone.0049492.t002
stage. It is only quasi steady-state because both viral replication and T cell source capacity are slowly declining (very slowly initially) with integrated viral load. At this stage $V$ is about 50 mm$^{-3}$ and CD4+ T cell count is just over 600 mm$^{-3}$. Since all population counts are per mm$^3$ (microliter) this unit will be implied in what follows unless stated otherwise. We also refer to CD4+ T cell count simply as “CD4”.

For the first four years CD4 and viral load remain fairly steady and then from years 4–7 CD4 declines gradually to 360 and viral load increases to 135. After the asymptomatic period the integrated viral load has increased and resulted in a declining capacity of the body to generate new CD4+ T cells concurrently with increased viral replication. This simulates immune collapse to AIDS which is firmly established from year 10 when CD4 has fallen below 50 and viral load has risen to almost 800. The macrophage population remains fairly constant at 196 (small reduction due to HIV infection of macrophages) until the AIDS stage when it decreases to about 150.

Figure 2B shows the 2-year period (years 7.5–9.5) with ART started at 8.5 years when $V = 520$ and CD4 = 99. $V$ falls below the undetectable threshold of 0.05 in 7.3 weeks and CD4 recovers over the next 6–12 months to almost 700.

doi:10.1371/journal.pone.0049492.g002
decline in 2 weeks. By this time CD4 has recovered to 313 and continues to rise to 680 by 9.5 years and reaches 694 by the start of year 10, 18 months after treatment. CD4 does not return to the pre-HIV level of 1000 because some T cell source capacity has been permanently lost. The 6 months after treatment, during which CD4 recovers to about 600 (85% of the final level), is a time of rapid immune restoration and hence the period of risk of IRIS.

Figure 3 depicts MTB infection only over 3 years for various parameter values. Infection starts at \( t = 0 \) with initial bacterial level \( B = 10 \). After about 18 months \( B \) reaches a maximum value. Normally the model allows \( H_0 \) to proliferate in response to \( B \) but here \( H_0 \) is kept fixed. The lowest curve has full CD4 capacity \( (H_0 = 1000) \) and a macrophage activation rate \( a_M = 0.2 \) that is double that for all the other curves. Immune suppression is strong and \( B \) reaches 130. With \( a_M = 0.1 \) bacterial level increases to 270. Then as \( H_0 \) is decreased in steps to 50, the maximum level of \( B \) continues to rise to 1355. Hence the model simulates active MTB infection that is controlled, but never eliminated, as a function of immune system strength.

HIV-MTB co-infection is modelled in Figure 4. HIV infection starts at \( t = 0 \) and MTB infection at 3 years. Panel A shows that bacterial level rises over the following year to 400 after which its rise slows due to reasonable immune control. The macrophage population rises due to recruitment stimulated by MTB infection. By year 6 CD4 falls below 500, the immune system starts to collapse, and bacterial level starts to rise and attains a new maximum of 1362. Viral load increases to over 1000, higher than for HIV infection only due to an increase caused by MTB of around 27% in viral replication. Progression to AIDS is also more rapid than for HIV only due to the increased integrated viral burden. CD4 has fallen to below 50 by year 8, almost two years earlier than for HIV alone.

Figure 4B is a plot of the macrophage and CD8+ T cell populations. The productive HIV-infected T cells and macrophages are not shown because their levels are low (less than 10). Resting macrophages \( (M_R) \) and MTB-specific CD8+ T cells \( (K_R) \) are stable until MTB infection at year 3. After infection the total macrophage population rises to 300 at first and then to 430 during advanced HIV disease. During MTB infection the activated macrophages \( (M_A) \) rise rapidly to a level of about 40, somewhat below \( M_R \), and then decline during AIDS because the lack of CD4+ T cells reduces macrophage activation. \( K_R \) follows a similar pattern to \( M_A \) for the same reasons. The MTB-infected macrophages in the non-productive eclipse stage \( (M_E) \) are paralleled at a lower level by the productive population \( (M_P) \). Their total \( (M_R+M_P) \) first rises to about 120 (40% MTB infection prevalence rate) and then to 300 (70% prevalence) during AIDS.

Modelling co-infection treatment strategies

Having tested the model’s capacity to simulate HIV-MTB co-infection it is extended to include several combined treatment strategies. Expert reviews [1]-%[4] recommend starting with TB treatment, with ART delayed according to CD4 count as follows:

- CD4 \( >200 \): About 6 months (end of TB treatment) because “Drug-drug interactions are better avoided than managed” [1]
- CD4 \( <200 \): 2–3 months [1], [4]
- CD4 \( <50 \): A few weeks [4]

Clinical trials have tested similar timings [6]. SAPIT [5] (for CD4 \( <50 \), and 50 \( < \) CD4 \( <200 \)) had delays after start of TB treatment of 15–30 days (earlier ART) and 77–126 days (later ART). The CAMELIA trial [8] (for CD4 \( <200 \)) had early ART at 2 weeks and later ART at 8 weeks.

To cover the reviewed range of timings we tested treatment strategies with delays of 15 days, 2 months and 6 months between start of TB treatment and start of ART. The results are shown in Figure 5. The earliest ART (15 days) is highly effective. The late ART (6 months) is ineffective while early ART (2 months) and delayed ART (2 months) are more effective than single treatment (alone with earlier ART). These results are consistent with those of the expert recommendations [1]-%[4].
1. Early HIV disease, when CD4 is between 200 and 350. MTB infection starts at 5.5 years and earliest treatment at 7 years (Figure 5).

2. Late HIV disease, when CD4 is between 50 and 200. MTB infection starts at 7 years and earliest treatment at 8 years (Figures 6 and 7).

3. AIDS stage, when CD4 is below 50. MTB infection starts at 8.5 years and earliest treatment at 9.5 years (Figure 8).

The MTB infection may be new, or reactivation of a latent infection, and in either case we assume that the infection becomes active fairly rapidly due to a weakened immune system. We assume further that after the bacterial load has exceeded about 500 the individual presents with symptoms that lead to treatment a short time later, and that bacterial load significantly higher than 500 could be fatal if it continues for more than a few months. TB treatment is administered for 6 months. For each timing one or more of the following strategies are implemented:

1. TB treatment first, followed after 6 months by ART
2. TB treatment first, followed after 2 months by ART
3. TB treatment first, followed after 15 days by ART
4. ART first, followed after 2 months by TB treatment
5. ART first, followed after 6 months by TB treatment

Figure 4. Simulation of HIV-MTB co-infection, without treatment. The panels show different populations in a simulation of HIV-MTB co-infection without treatment. HIV infection starts at $t=0$ and MTB infection at $t=3$ years. Panel A shows CD4, viral load, bacterial level and total macrophage population. Since CD4 $\geq$ 500 $\mu$L$^{-1}$ at $t=3$ years the immune system is relatively strong and $B$ reaches a maximum level that starts to rise again as HIV disease progresses to AIDS. By the AIDS stage, $B$ reaches a maximum of 1362. $V$ reaches 1065 which is higher than the HIV-only maximum due to increased viral replication induced by MTB. The macrophage population rises from its 200 resting level to about 300 during MTB infection and then to about 430 during AIDS due to a decrease in activation that allows increased MTB infection. Panel B shows the smaller populations. Macrophages are activated by MTB but lost to HIV infection and especially MTB infection, with the loss increasing during AIDS. The CD8+ T cell population $K_B$ proliferates in response to the infections.

doi:10.1371/journal.pone.0049492.g004
We set ARV parameters $\varepsilon_R = \varepsilon_P = 0.75$ and anti-TB drug parameters $\varepsilon_C = \varepsilon_S = 0.5$. These values clear the infections in reasonable time ($B$ below 1 in 6 months, $V$ below 0.05 in 8 weeks). In strategies 2–5 we assume that drug interaction may be operating in which case we set the efficacy reduction parameter $d$ to 0.75. Strategies 4 and 5 are not recommended by expert reviews [1–4] but are included for completeness in order to see what happens (according to the model) if ART starts first. The idea is that a recovered (or recovering) immune system could assist TB treatment in recovery from MTB infection. Key values for the timings and strategies are summarised in Table 3.

### Timing 1: Early HIV disease

Figure 5 shows presentation of TB during early HIV disease. MTB infection starts at 5 years 6 months. Panel A shows the scenario without treatment. By year 7, $B$ has increased to 779 and $V$ to 248, and CD4 has fallen to 268. Panel B shows strategy 1: TB treatment first at 7 years, followed by ART 6 months later on cessation of TB treatment. $B$ falls rapidly during the first 3 months of treatment and is eliminated ($B<1$) in 25 weeks. Then ART reduces HIV below the undetectable threshold ($V<0.05$) in 7 weeks. Immune reconstitution follows with a rapid rise in CD4 over 6 months.

Figure 5C shows strategy 2: ART started after 2 months of TB treatment, with no drug interaction. Reduction in $B$ has the positive secondary effect of reducing $V$. There is earlier immune reconstitution than for strategy 1, with risk of TB IRIS only during the late phase of TB treatment when $B$ is low and the patient is recovering from TB. However, drug interaction (Figure 5D) results in diminished suppression of viral load after ART starts (compared with Figure 5C) and hence a delayed recovery of CD4. There is not much benefit from this strategy compared to starting ART 6 months after TB treatment, and the risk of TB IRIS is higher. However, this is all for early HIV disease; the differences between strategies is more marked for the late HIV disease timing.

### Timing 2: Late HIV disease

Figure 6 shows TB presentation during late HIV disease. MTB infection starts at 7 years, and by 8 years $B=727$, $V=472$ and CD4 = 133. The no-treatment scenario is presented in Figure 6A. ART 6 months after TB treatment starts (strategy 1) is shown in Figure 6B. $V$ dips after TB treatment but remains high (above 477) for 11 months. In this case, drug interaction is not so important; the $B$ level is monotonically decreasing, but $V$ may be slightly increased.

\[\text{Figure 5. Simulation of combined treatment during early HIV disease.}
\]

Panel A (no treatment) shows MTB infection that starts at 5 years 6 months, and by year 7 when treatment starts bacterial load rises to 779 mL$^{-1}$ and CD4 is 268 mL$^{-1}$. In all cases, TB treatment starts at 7 years and ART after a delay. Panel B shows late ART (strategy 1: delay of 6 months). MTB infection has been eliminated by the time ART begins so there is no drug interaction, no overlap of drug toxicity and no TB IRIS. CD4 falls to about 200 and then recovers. Panel C shows early ART (strategy 2: delay of 2 months) with anti-TB drug interaction, which allows CD4 to remain stable and then recover, but there is some overlap of drug toxicities. There is also risk of TB IRIS, but bacterial level is low. Panel D shows the same scenario as for panel C but with drug interaction that moderately increases viral replication and delays CD4 recovery.

doi:10.1371/journal.pone.0049492.g005
Figure 6. Simulation of combined treatment during late HIV disease. Panel A is the no treatment scenario with MTB infection starting at 7 years. By year 8, $B = 727 \, \mu\text{L}^{-1}$, $CD4 = 133 \, \mu\text{L}^{-1}$ and $V = 472 \, \mu\text{L}^{-1}$. All treatment scenarios start with TB treatment first at 8 years. Panel B shows ART starting at 8 years 6 months (strategy 1). The outcome is as for Figure 5B except that $V$ is much higher and CD4 falls below 100. This puts the patient at higher AIDS-associated risk than with earlier ART. Panel C shows immediate ART starting 15 days after the start of TB treatment (strategy 3), with no drug interaction. CD4 recovery is early but $B$ is high during the steepest rise of CD4 so risk of TB IRIS is high. Adding drug interaction (panel D) causes a resurgence of $V$ and a delay in CD4 recovery although CD4 remains stable at around 200. Panel E has early ART starting after 2 months with no drug interaction (strategy 2). CD4 remains stable for the 2 month period and then recovers. Bacterial level is relatively low during CD4 recovery so risk of TB IRIS is less than for immediate ART. Panel F adds drug interaction which as in Panel D delays CD4 recovery, but for 6 rather than 2 months.

doi:10.1371/journal.pone.0049492.g006
350). CD4 remains low (after a minor initial increase) and falls slowly to below 100 by the start of ART. Once ART is initiated CD4 recovers. Figure 6C displays strategy 3: ART starts 15 days after TB treatment, with no drug interaction. Both infections decline rapidly, which is the best outcome, but the rapid rise in CD4 overlaps with the early phase of treatment when the patient still has TB. With drug interaction (Figure 6D) the outcome is not so positive: V rebounds and recovery of CD4 is delayed by 6 months. Finally, strategy 2 (ART 2 months after TB treatment) is shown in Figure 6E, with no drug interaction. Since CD4 recovery occurs when B is low there is lower risk of TB IRIS than for earlier ART. The negative aspect is a 2 month extension of low CD4. Figure 6F adds drug interaction, which delays CD4 recovery in a similar manner to that shown in Figure 6D but is still better than a 6 month delay in ART if compared with Figure 6B.

Although starting ART first is not a recommended strategy [1–4], we investigate it for completeness in Figure 7 with the motivation that once there is sufficient immune reconstitution after ART it could help TB treatment. Figure 7A shows strategy 4: TB treatment starts 2 months after ART, with no drug interaction. Due to suppression of viral load and recovery of CD4 the rise in B is reversed but B remains high so the risk of death from TB remains present. The patient has active TB that continues for 2 months at a high level and overlaps with CD4 recovery so risk of TB IRIS is high. The situation is aggravated by drug interaction (Figure 7B) by a resurgence of V when the anti-TB drugs reduce ARV drug absorption. There is an associated fall in CD4 and then the patient experiences immune reconstitution a second time. Strategy 5 (Figure 7C: TB treatment starts 6 months after ART) extends active TB by 6 months (with, however, some further reduction of B due to improved immune response) with greater overlap of potential IRIS and TB. Adding drug interaction (Figure 7D) aggravates the situation with a similar pattern as in Figure 7B.

**Timing 3: AIDS**

The final timing is presentation of TB during AIDS, when CD4 is below 50 (Figure 8). TB treatment had to be extended by one week (to 6.25 months) in order to clear MTB infection. Panel A shows the no-treatment scenario. After MTB infection at 8 years 6 months, B rises to about 1000 by 9 years 6 months, when V is also about 1000. CD4 is below 50, and remains stable in the model.

---

**Figure 7. Simulation of ART before TB treatment during late HIV disease.** As for Figure 6 this simulation is of late HIV disease but with ART started first at 8 years. In panel A, TB treatment starts 2 months after ART begins (strategy 4). Drug interaction is not included. Viral load falls rapidly and CD4 recovers immediately. The strengthened immune system slows and then reverses bacterial growth just before TB treatment starts, but MTB infection remains strong. A high risk of TB IRIS as well as ongoing TB are negative outcomes. Drug interaction (panel B) worsens the situation with a resurgence of V and a delay in CD4 recovery. Delaying ART by 6 months to allow the immune system a longer time to act against TB (strategy 5; panel C) simply extends the period of high bacterial load. Drug interaction (panel D) allows resurgence of V and a renewed collapse of CD4 before it recovers again.

doi:10.1371/journal.pone.0049492.g007
although in reality it could decline. For the purpose of illustration, Figure 8B shows TB treatment first at 9 years 6 months followed by ART 6 months later (strategy 1). Although TB IRIS and drug interaction are avoided, and MTB is eliminated, the continued high viral load and low CD4 over 6 months pose significant risk of AIDS death. Strategy 3 with no drug interaction (Figure 8C) suppresses both infections rapidly and allows CD4 to recover immediately, although with a risk of TB IRIS. Drug interaction
shown in Figure 8E (no drug interaction). Risk of TB IRIS is low CD4 (slightly improved to 70) for 6 months. Strategy 2 is

Discussion

(Figure 8D) extends high V'(although at 550 rather than 1000) and low CD4 (slightly improved to 70) for 6 months. Strategy 2 is shown in Figure 8E (no drug interaction). Risk of TB IRIS is diminished at the cost of a 2 month extension of low CD4. With drug interaction (Figure 8F) the situation is similar to Figure 8D.

Table 3. Summary of HIV-MTB co-infection and treatment scenarios.

| Infection or treatment scenario | Time (years) | CD4 (mm$^3$) | HIV (mm$^3$) | MTB (mm$^3$) |
|---------------------------------|-------------|--------------|-------------|-------------|
| HIV-MTB co-infection, no treatment |             |              |             |             |
| HIV infection starts            | 0           | 1000         | 0.01        | 0           |
| Early asymptomatic stage        | 1.5         | 619          | 49          | 0           |
| MTB infection starts            | 3           | 604          | 52          | 10          |
| Late asymptomatic stage         | 6           | 439          | 122         | 609         |
| AIDS                            | 9           | 40           | 1065        | 1362        |
| Early HIV disease               |             |              |             |             |
| (200<CD4<350)                   |             |              |             |             |
| TB treatment starts first       | 7           | 268          | 248         | 779         |
| ART starts 2 months later       | 7.17        | 269          | 189         | 29          |
| ART starts 6 months later       | 7.5         | 214          | 261         | 0           |
| Late HIV disease                |             |              |             |             |
| (50<CD4<200)                    |             |              |             |             |
| TB treatment starts first       | 8           | 133          | 472         | 727         |
| ART starts 15 days later        | 8.04        | 126          | 375         | 134         |
| ART starts 2 months later       | 8.17        | 131          | 423         | 33          |
| ART starts 6 months later       | 8.5         | 93           | 543         | 0           |
| Late HIV disease                |             |              |             |             |
| (50<CD4<200)                    |             |              |             |             |
| ART starts first                | 8           | 133          | 472         | 727         |
| TB treatment starts 2 months later | 8.17      | 455          | 0.01        | 923         |
| TB treatment starts 6 months later | 8.5       | 796          | 3 x 10^-8   | 508         |
| AIDS (CD4<50)                   |             |              |             |             |
| TB treatment starts first       | 9.5         | 44           | 989         | 989         |
| ART starts 15 days later        | 9.54        | 49           | 757         | 179         |
| ART starts 2 months later       | 9.67        | 49           | 796         | 44          |
| ART starts 6 months later       | 10          | 49           | 799         | 6           |

doi:10.1371/journal.pone.0049492.t003

Various treatment strategies have been tested but we have not yet weighed the results. It is beyond the scope of this study to estimate probabilities of outcomes, so to decide between strategies we propose a simple method based on a set of risks, assuming that the risk of drug interaction is avoided by a suitable choice of drugs. The risks have quantitative measures to classify them qualitatively as low, medium or high but we do not attach a probability to each risk level. The risks are listed below, with definitions given for medium and high risk, and low risk assumed otherwise.

1. AIDS-related death due to low CD4 count. Risk is medium if CD4<50 for 2 months, or 50<CD4<200 for 6 months. Risk is high if CD4<50 for 6 months
2. TB-related death due to high MTB load (B>500). Risk is medium if high MTB load persists for 2 months, and high if it persists for 6 months
3. Adverse effects of overlap of drug toxicities, measured by timing and duration of overlap. Risk is high during the first 2 month phase of TB treatment, and medium during the second 4 month phase
4. TB IRIS, measured by MTB load during the immune reconstitution period (6 months of rapid increase of CD4). Risk is high if B>50, and medium if 1<B<50.

Based on these risks, strategies are chosen by the following criteria, in order of preference:

1. Low risks only
2. Low risk of both AIDS-related and TB-related death
3. Low and medium risks only

Table 4 shows risk levels for the simulated treatment strategies. In general, early ART after TB treatment is better than late ART provided that TB IRIS and drug interaction are minimised. This depends on HIV disease stage. For early HIV disease a longer delay of ART is acceptable because CD4 remains relatively high. Strategy 1 is best since it has low risks only whereas strategy 2 (earlier ART) has medium levels of risks 3 and 4. For late HIV disease strategy 2 is best: initiate ART 2 months after TB treatment starts. A 6 month delay has risk of AIDS death at medium level whereas a 15 day delay has high levels of risks 3 and 4. Strategies 4 and 5 (ART first) for late HIV disease are inferior to strategies 2 and 3 because of medium to high risk of TB-related death and high levels of risks 3 and 4. During AIDS, strategy 3 is best (15 day delay of ART) because risk of AIDS-related death is low compared to strategies 1 and 2. Strategy 3 minimises the time spent with critically low CD4. Medium risk of AIDS-related death in strategy 2 is a worse outcome than high levels of risks 3 and 4 in strategy 3. Drug interaction complicates the strategies, especially during AIDS, when resurgence of viral load and associated suppression of CD4 increase the risks of AIDS-related death and TB IRIS. These results are consistent with expert recommendations [1–4] and with results from clinical trials (SAPIT [5], [7], CAMELLIA [8], and [9]).

What new knowledge do the simulations provide? First, the model agrees with expert reviews and clinical results and supports current understanding. If the simulations were to diverge from observations it would be necessary to review the mechanisms in the model. But in fact there is convergence, which is evidence that the theory in the model is consistent with empirical data. Second, the model was able to test, however approximately, a strategy to treat HIV first. This strategy is neither proposed in expert reviews [1–4] nor included in clinical trials [3–9] but is nevertheless a strategy that is possible and that can easily be tested with a
The results indicate that it is not a good strategy. The third aspect highlighted by the simulations is the potential risk of drug interaction. In all cases the benefits of early ART were negated by drug interaction that increased viral load and suppressed CD4 count. Especially in resource-poor settings the risk of drug interaction cannot be ignored.

In summary, the model is able to simulate the disease-treatment process, albeit in a highly-simplified and approximate manner. It is far from capturing the full complexity of the system, but it is nevertheless based on biomedical science and clinical data. Its features could be improved to provide an increasingly realistic simulation that serves as a testing and decision tool. The criteria for deciding between strategies could be coded into a more robust quantitative measure. This could incorporate rate of change of CD4 as a measure of IRIS risk, as well as viral and bacterial load, drug toxicity, and improved measures of drug interaction. Such a model could help in designing new clinical trials, with a range of scenarios tested in advance.

Further work could address mechanisms of HIV disease progression, suppressed, latent and active MTB infection, and granuloma and tubercle formation. TB drug resistance could be modelled. As a step toward multi-scale simulation the host-pathogen model could be embedded in a population-level epidemiological model. All of these avenues will be navigated best by multi-disciplinary collaboration.

**Supporting Information**

**Appendix S1 Analysis of the model.** The analysis has three parts. First, the quasi-equilibrium state is analysed on time-scales short compared with the time scale of progression to AIDS. Second, simulations are run for a reduced model that does not have activated macrophages \( M_A \) or the eclipse-stage populations \( H_E \) and \( M_E \), in order to investigate the necessity of these populations. Third, simulations are run without the immune response to see to what extent it is necessary for modelling treatment of HIV-MTB co-infection and treatment.

**Figure S1 CD8+ killer T cell dependence on infected cell level.** CD8+ killer T cell level \( K \) in the equilibrium state is plotted against infected cell level \( I \) for various values of \( h = H_S/H_P \). \( K \) is the solution of the quadratic equation S2. The \( K \) curves all lie between \( K_{sf} = 10 \) and \( K_{max} = 100 \) cells per microliter. Each curve rises with increasing \( I \) as proliferation of \( K \) is stimulated, and \( K \) stabilises above the \( I \) half-saturation level of 2.5. The maximum of \( K \) decreases as \( h \) decreases.

**Figure S2 CD4+ helper T cell dependence on pathogen level.** CD4+ helper T cell level \( H_P \) in the equilibrium state is plotted against the combined pathogen level \( P = V \) (HIV)+B (MTB). Various curves are shown for different values of HIV-specific CD8+ killer T cell level \( K_f \) and HIV proportion \( V/P \). The upper curve \((V/P=0, K_f=50)\) is almost constant since there is no loss of \( H_P \) to infection and rises slightly with \( B \) due to increased proliferation. The curves with \( V/P>0 \) decrease with pathogen level even for a small proportion of \( V \). Three curves are shown keeping \( V/P \) constant but varying \( K_f \) from \( K_{sf} \) to \( K_{max} \). Although there is some dependence on \( K_f \) \((H_P \) decreases as \( K_f \) decreases\) the main dependence is on \( V \), by loss to HIV infection.

**Figure S3 Macrophage populations as functions of MTB level.** Equilibrium macrophage levels are plotted against bacterial load \( B \). The dashed line is the total of macrophages in the following states: resting \( M_R \), activated \( M_A \), MTB-infected eclipse-stage \( M_E \) and productively infected \( M_P \). Total macrophage population increases with \( B \) and stabilises above the half-saturation level of \( B = 500 \). Resting macrophages rise at first from the disease-free level of 200 but then fall due to loss to infection. Activated macrophages increase and then stabilise above the half-saturation level.

---

**Table 4. Summary of treatment outcomes.**

| Treatment strategy       | AIDS death | TB death | Drug overlap | TB IRIS |
|--------------------------|------------|----------|--------------|---------|
| Early HIV disease, TB treatment first |            |          |              |         |
| ART starts 6 months later (strategy 1) | low       | low      | low          | low     |
| ART starts 2 months later (strategy 2) | low       | medium   | medium       | medium  |
| Late HIV disease, TB treatment first |          |          |              |         |
| ART starts 6 months later (strategy 1) | medium    | low      | low          | low     |
| ART starts 2 months later (strategy 2) | low       | medium   | medium       | medium  |
| ART starts 15 days later (strategy 3)  | low       | low      | high         | high    |
| Late HIV disease, ART first |            |          |              |         |
| TB treatment starts 2 months later (strategy 4) | low       | medium   | high         | high    |
| TB treatment starts 6 months later (strategy 5) | low       | high     | high         | high    |
| AIDS, TB treatment first |            |          |              |         |
| ART starts 6 months later (strategy 1)  | high      | low      | low          | low     |
| ART starts 2 months later (strategy 2)  | medium    | low      | medium       | medium  |
| ART starts 15 days later (strategy 3)  | low       | low      | high         | high    |

*The four risks are negative events that should be avoided. Risk is low, medium or high. A strategy is preferred first if it has low risks only, second if it has low risk of both AIDS-related and TB-related death, and third if it has low and medium risks only.

doi:10.1371/journal.pone.0049492.t004
level, also $B = 500$, but fall slightly at high $B$. Eclipse-stage and productive-stage populations both rise with $B$.

(PDF)

**Figure S4** Dependence of MTB load on CD4+ and CD8+ T cell levels. Equilibrium bacterial load $B$ is plotted against MTB-specific CD8+ killer T cell level $K_B$ in panel A and against $h = H_s/H_d$ in panel B. Curves are plotted for various values of resting macrophage population $M_R$ in panel A and of activation parameter $a_{Hs}$ in panel B. Panel A shows that $B$ depends strongly on $K_B$ in the range 0–20 cells per microliter but does not vary much as $K_B$ increases to 100. There is less dependence on $M_R$. Panel B shows that $B$ decreases strongly with $h = H_s/H_d$ and with increasing $a_{Hs}$. This is due to the dependence of the activated macrophage population on the product $a_{Hs} M_R$.

(PDF)

**Figure S5** Simulation of HIV-MTB co-infection with reduced model. The graph shows the same scenario as in Figures 2A and 4A, but with the reduced model in which $M_R$, $M_P$, and $H_d$ are omitted. The absence of eclipse-stage populations results in shortened time-lags. Panel A shows the HIV-only simulation in which the initial spike in $V$ is much sooner (day 4) and much higher (30 000 mm$^{-3}$) than for the full model. Panel B (HIV-MTB co-infection) shows that MTB infection results in a sudden rise of bacterial load to its maximum level, which does not model the characteristic slow growth of MTB.

(PDF)

**References**

1. Burman WJ, Jones BE (2001) Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 164: 7–12.

2. Dean GL, Edwards NG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16: 75–83.

3. Kwaara A, Flanigan TP, Carter EJ (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis. Current status. Int J Tuberc Lung Dis 9(3): 248–257.

4. McIlroy H, Meinjies G, Burman WJ, Maartens G (2007) Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196: 863–75.

5. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365(16): 1492–1501.

6. Piggott DA, Karakousis PC (2011) Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol. 2011: Article ID 103917, 10 pages. doi:10.1155/2011/103917.

7. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362(9): 697–706.

8. Blanc FX, Sok T, Laurillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New Engl J Med 365(16): 1471–1481.

9. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and AIDS. J Theor Med 4(4): 215–221.

10. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and virion generation time. Science 271(5255): 1506–1509.

11. Rapin N, Keszin C, Frankild S, Nielsen M, Lundegaard C, et al. (2006) Modelling the human immune system by combining bioinformatics and systems biology approaches. J Biol Phys 32: 335–353.

12. Rong L, Perelson AS (2009) Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 5(10): e1000533. doi:10.1371/journal.pcbi.1000533.

13. Sadjadat AR, Dinso JB, Shen L, Wilke CO, Siliciano RF (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 105(12): 4832–4837.

14. Shiri T, Garira W, Musekwa SD (2005) A two-strain HIV-1 mathematical model to assess the effects of chemotherapy on disease parameters. Math Biosci 199(1): 1–12.

**Author Contributions**

Conceived and designed the experiments: SR HGM APM. Performed the experiments: SR APM. Analyzed the data: SR HGM APM. Wrote the paper: HGM APM. Finalization of research question and objectives: HGM Model conception and design: SR Initial literature review: SR HGM Modelling approach: SR APM Revision of literature review, model, experiments and data analysis: APM.

(PDF)
33. Magombedze G, Garira W, Mwenje E (2006) Mathematical modeling of chemotherapy of human TB infection. J Biol Syst 14(4): 509–553.
34. Magombedze G, Garira W, Mwenje E (2009) The role of dendritic cells and other immune mechanisms during human infection with *Mycobacterium tuberculosis*. Int J Biomath 2(1): 69–105.
35. Marino S, Kirschner DE (2004) The human immune response to *Mycobacterium tuberculosis* in lung and lymph node. J Theor Biol 227: 463–486.
36. Marino S, Sud D, Plessner H, Lin PL, Chan J, et al. (2007) Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLos Comput Biol 3(10): e194. doi:10.1371/journal.pcbi.0030194.
37. Sud D, Bigbee C, Flynn JL, Kirschner DE (2006) Contribution of CD8$^+$ T cells to control of *Mycobacterium tuberculosis* infection. J Immunol 176: 4296–4314.
38. Wigginton JE, Kirschner D (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with *Mycobacterium tuberculosis*. J Immunol 166: 1951–1967.
39. Bauer AL, Hogue IB, Marino S, Kirschner DE (2008) The effects of HIV–1 infection on latent tuberculosis. Math Model Nat Phenom 3(7): 229–266.
40. Kirschner D (1999) Dynamics of co-infection with *M. tuberculosis* and HIV-1. Theor Popul Biol 55: 94–109.
41. Magombedze G, Garira W, Mwenje E (2008) In-vivo mathematical study of co-infection dynamics of HIV-1 and *Mycobacterium tuberculosis*. J Biol Syst 16(3): 357–394.
42. Magombedze G, Garira W, Mwenje E (2010) Modeling the TB/HIV-1 co-infection and the effects of its treatment. Math Popul Stud 17(1): 12–64.
43. Dimitrov DS, Willey RL, Sato H, Chang L-J, Blumenthal R, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67(4): 2182–2190.
44. Almquist JB, Ball TB, Foske KR (2003) Mechanisms of CD4$^+$ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84: 1649–1661.
45. Gendelman HE, Orenstein JM, Bacca LM, Weser B, Burger H, et al. (1989) The macrophage in the persistence and pathogenesis of HIV infection. AIDS 3(8): 475–496.
46. Orenstein JM, Fox C, Wahl SM (1997) Macrophages as a source of HIV during opportunistic infections. Science 276(5320): 1857–1861.
47. Tossi Z (2003) Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 188: 1146–1155.
48. Johnson LF, Dorrington RE, Matthews AP (2007) A Bayesian approach to uncertainty analysis of HIV/AIDS models. South Afr J Sci 103: 133–140.
49. Leclerc PM, Matthews AP, Garenne M (2009) Fitting the HIV epidemic in Zambia: A two sex micro-simulation model. PLos ONE 4(3): e5439. doi:10.1371/journal.pone.0005439.
50. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RMM, Paul WE (2002) CD4$^+$ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nature Medicine 8(4): 319–323.
51. Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 214: 231–241.
52. Wick WD, Yang OO, Corey L, Self SG (2005) How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol 79(21): 13579–13586.